Literature DB >> 3888577

Behavioral pharmacology of buprenorphine.

N K Mello, J H Mendelson.   

Abstract

Buprenorphine is an opioid mixed agonist-antagonist that has potential usefulness as a pharmacotherapy for opiate addiction. Buprenorphine significantly suppressed opiate self-administration by heroin addicts. Buprenorphine also suppressed opiate self-administration in a primate model. Although buprenorphine is a positive reinforcer in rhesus monkey, it is less reinforcing than other opioids and some opioid mixed agonist-antagonists as evaluated in progressive ratio and drug substitution procedures. These data suggest that the abuse liability of buprenorphine should be less than that of other opioid drugs. The safety and potential therapeutic benefits of buprenorphine relative to other currently available pharmacotherapies probably overweigh the possible risks of abuse.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3888577     DOI: 10.1016/0376-8716(85)90062-6

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  17 in total

1.  Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Authors:  Jermaine D Jones; Maria A Sullivan; Suzanne K Vosburg; Jeanne M Manubay; Shanthi Mogali; Verena Metz; Sandra D Comer
Journal:  Addict Biol       Date:  2014-07-25       Impact factor: 4.280

Review 2.  Indications for Opioid Antagonists.

Authors:  O J Michael Coppes; Christine N Sang
Journal:  Curr Pain Headache Rep       Date:  2017-06

Review 3.  Methadone maintenance in the treatment of opioid dependence. A current perspective.

Authors:  J E Zweben; J T Payte
Journal:  West J Med       Date:  1990-05

Review 4.  Update on the clinical use of buprenorphine: in opioid-related disorders.

Authors:  Simon Ducharme; Ronald Fraser; Kathryn Gill
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

5.  Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland.

Authors:  Becky L Genberg; Mirinda Gillespie; Charles R Schuster; Chris-Ellyn Johanson; Jacquie Astemborski; Gregory D Kirk; David Vlahov; Shruti H Mehta
Journal:  Addict Behav       Date:  2013-08-17       Impact factor: 3.913

6.  The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.

Authors:  Jermaine D Jones; Gabriela Madera; Sandra D Comer
Journal:  Pharmacol Biochem Behav       Date:  2014-05-02       Impact factor: 3.533

Review 7.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

Review 8.  Controversies in translational research: drug self-administration.

Authors:  Margaret Haney; Roger Spealman
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

9.  Morphine deprivation increases self-administration of the fast- and short-acting mu-opioid receptor agonist remifentanil in the rat.

Authors:  Ziva D Cooper; Yen Nhu-Thi Truong; Yong-Gong Shi; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2008-05-30       Impact factor: 4.030

10.  A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.

Authors:  Yafang Zhang; Suditi Rahematpura; Kael H Ragnini; Amanda Moreno; Kamryn S Stecyk; Michelle W Kahng; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neuropharmacology       Date:  2021-05-11       Impact factor: 5.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.